Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron 50 mg vs placebo in neurogenic detrusor overactivity
2014-002592-29Phase 3Completed
- Sponsor
- University Hospital Ostrava
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in detrusor hyperreflexia (DH), spinal cord injury (SCI) and multiple sclerosis (MS) comparing Mirabegron 50 mg with Placebo (2 arms). Primary endpoint: Change of maximal cystometric capacity. Started Dec 2014; status: completed.
02
Drugs
mirabegron
03
Conditions
detrusor hyperreflexia (DH)spinal cord injury (SCI)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-002592-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002592-29.